Saturday 17 October 2026
Export LIPO’s income statement to Excel — free account
Lipella Pharmaceuticals Inc.
LIPO Healthcare Biotechnology
Lipella Pharmaceuticals Inc.’s revenue for fiscal 2024 (year ended December 2024) was $536,400.00, up 19.3% from fiscal 2023. In the quarter to September 2025, revenue fell 36.4%, EPS grew 78.3% and free cash flow fell 41.8%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
0.00
0.00
NaN
Follow LIPO
| Older periods | Dec '24 | Mar '25 | Jun '25 | Sep '25 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
— | — | 3 | — |
| (198.12%) | (154.54%) | (248.35%) | (361.77%) | ||
| (160.49%) | (128.38%) | (186.99%) | (236.36%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(267.84%) | (126.51%) | (204.55%) | (368.95%) | |
Average Days of Receivables |
57.64 | 60.10 | 32.60 | — | |
Free Cash Flow per Share |
(3.77) | (1.94) | (1.05) | (1.05) | |
Free Cash Flow |
(3.95) | (3.99) | (4.50) | (4.78) | |
| Other line items | |||||
Cash ROIC |
(96.26%) | (48.03%) | (81.52%) | (142.84%) | |
Accounts Receivable Turnover |
9.17 | 6.73 | 12.17 | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
673.60% | 724.00% | 828.18% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
373.55% | 374.40% | 461.74% | 0.00% | |
Share Based Compensation of Revenue |
176.99% | 0.00% | 0.00% | — | |
Operating CF/Net income |
0.79 | 0.78 | 0.82 | 0.90 | |
Depreciation/Fixed assets |
0.29 | 0.32 | 0.35 | 0.38 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Revenue per Share |
0.51 | 0.25 | 0.11 | 0.00 | |
Operating CF per Share |
(3.77) | (1.94) | (1.05) | (1.05) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | — |
Columns are period end dates